

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19383 A1

(51) International Patent Classification⁷: **A61K 35/78, A23L 1/30, 1/303** [US/US]; 2106 Riverforest Drive, Arlington, TX 76017 (US).

(21) International Application Number: **PCT/US00/24439** (74) Agents: BROWN, Gregg, C. et al.; Alcon Universal Ltd., c/o Alcon Research, Ltd., R & D Counsel, Mail Code Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).

(22) International Filing Date:
6 September 2000 (06.09.2000)

(25) Filing Language: English

(81) Designated States (*national*): AU, BR, CA, JP, MX, TR, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Priority Data:
09/397,472 17 September 1999 (17.09.1999) US


(71) Applicant (*for all designated States except US*): ALCON UNIVERSAL LTD. [CH/CH]; Bosch 69, P.O. Box 62, CH-6331 Hunenberge (CH).

Published:
— With international search report.

(72) Inventor; and

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(75) Inventor/Applicant (*for US only*): LANG, John, C.



WO 01/19383 A1

(54) Title: STABLE CAROTENE-XANTHOPHYLL BEADLET COMPOSITIONS AND METHODS OF USE

(57) Abstract: Beadlets comprising xanthophylls and carotenes and/or retinoids, dietary supplements comprising these beadlets and methods of use are disclosed.

Stable Carotene-Xanthophyll Beadlet Compositions and Methods of Use

5 Background of the Invention

Dietary supplements are taken for a variety of reasons including the improvement of vision or prophylaxis of vision loss. An example of a set of dietary supplements useful in promoting healthy eyes are the ICAPS® Dietary Supplements (Alcon Laboratories, Inc., Fort Worth, TX). Dietary supplements are generally in the form of powders, tablets, capsules or gel-caps and comprise a variety of vitamins, minerals, and herbal or other organic constituents. Some dietary supplements are formulated with beadlets.

Beadlets contain dietary substances and are generally small spheroids of less than about a millimeter in diameter. There are a variety of functions and purposes of beadlets. For example, beadlets may provide for the separate containment of ingredients within the dietary supplement to improve the stability of the entrapped ingredients.

Various beadlet compositions are known and can be obtained from a number of food ingredient or pharmaceutical manufacturers including H. Reisman Corp. (Orange, NJ), BASF (Mount Olive, NJ) and Hoffmann-LaRoche (Nutley, NJ). Particular beadlet compositions have been the subject of several patents including U.S. Patent Nos. 4,254,100 (Keller et al.) and 3,998,753 (Antoshkiw et al.). Methods of beadlet manufacture have been disclosed in U.S. Patent Nos. 4,670,247 (Scialpi) and 3,998,753.

Current beadlet compositions used in dietary supplements generally are restricted to the use of inert ingredients and excipients complementary to a single nutritional compound. In other instances, when molecules of the same class are refined from a particular source, for example a major component with a minor related constituent, and both compounds produce parallel effects, such molecules may not necessarily be isolated but mixed together in a

beadlet. These may be considered pseudo-single-component beadlets, and there are examples in the market place, e.g., Lutrinol® and FloraGLO® beadlets, which are a combination of lutein and zeaxanthin as formulated in Retoxil® Dietary Supplements. Examples of ingredients benefiting from beadlet confinement have included natural vitamins such as
5 Vitamins A, D, E, and K; xanthophylls such as lutein, zeaxanthin, canthaxanthin, and astaxanthin; and carotenes, such as beta-carotene, lycopene, and retinol.

Recent data has suggested that the inclusion of xanthophylls and other carotenoids in dietary supplements may provide superior dietary supplements useful in enhancing the health of the eye. Studies have shown the selective uptake of the carotenoids, zeaxanthin and lutein,
10 by the macula of the eye (Bernstein et al., *Retinal Tubulin Binds Macular Carotenoids*, Inv Ophthal & Vis Sci, volume 38, No. 1, pages 167-175 (1997); Hammond et al., *Dietary Modification of Human Macular Pigment Density*, Inv Ophthal & Vis Sci, volume 38, No. 9, pages 1795-1801 (1997); and Handelman et al., *Biological Control of Primate Macular Pigment: Biochemical and Densitometric Studies*, Inv Ophthal & Vis Sci, volume 32, No. 2, 15 pages 257-267 (1991)).

Xanthophylls are effective phytochemical antioxidants and are known to localize in the macula of the retina. It has been suggested that the particular xanthophylls, zeaxanthin and its isomer lutein, may be beneficial in improving the health of the macula and the clarity of the lens. These molecules may function in a number of ways to protect the eye from high
20 intensity radiation or other insults. It has been suggested that foveal proteins bind the xanthophylls and localize xanthophylls within the fovea. Since xanthophylls are capable of absorbing photoexcitative radiation of short visible wavelength, they also may shield the light-sensitive, underlying cells of the fovea. Such cells are responsible for high-definition vision and have been shown by epidemiological studies to be adversely affected by exposure
25 to high intensity radiation or even chronic exposure to visible wavelength radiation. The

carotenoids are believed to complement the activity of these cells, and also to protect them against photochemical insult. See, e.g., Snodderly, *Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins*, Am J Clin Nutr, volume 62(suppl), pages 1448S-1461S (1995) and Seddon et al., *Dietary Carotenoids, Vitamins A, C and E, and Advanced Age-Related Macular Degeneration*, JAMA, volume 272, No. 8, pages 1413-1420 (1994).

Studies have also shown that the portion of the retina associated with xanthophyll deposition undergoes one of the highest metabolic rates in the body (Berman, Biochemistry of the Eye, (Plenum, 1991). The energy to sustain this metabolism is derived from oxidation.

While xanthophylls do not appear to undergo rapid turnover characteristic of water-soluble antioxidants (Hammond, et al., *Dietary modification of human macular pigment density*, IOVS, volume 38, pages 1795-1801 (1997)), continuous exchange of xanthophylls occurs in response to both environmental challenge and tissue environment, and their depletion without nutritional replacement may portend tissue damage (Hammond, et al., *Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns*, Vision Research, volume 36, pages 2001-2012 (1996); Hammond, et al., *Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration*, Vision Research, volume 36, pages 3003-3009 (1996); and Seddon, et al., *Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration*, JAMA, volume 272, pages 1413-1420 (1994)).

The carotenes are conjugated C₄₀ compounds that include beta carotene (a provitamin A precursor). The carotenes are deeply colored compounds and are found throughout the plant kingdom, e.g., in leafy vegetables such as spinach and kale, and brilliantly colored fruits such as melons and pineapple. While the carotenes are ubiquitous in the plant kingdom, they generally are not available biosynthetically in mammals. Since the carotenes are essential for

normal mammalian health, mammals need to ingest various sources of the carotenes, e.g., fruits and vegetables. In particular, the absence of carotenoids from the diet, especially the carotene derivative, vitamin A, is known to be associated with degenerative eye diseases.

5 **Summary of the Invention**

The present invention is directed to improved beadlet formulations useful for inclusion in dietary supplements. In particular, the improved beadlets comprise one or more xanthophylls; one or more carotenes, retinoids or combinations thereof; one or more 10 antioxidants; and excipients. Preferred beadlets may also contain one or more bioflavonoids. The beadlets are particularly useful for incorporation in dietary supplements customized for improving ocular nutrition.

The present invention is also directed to improved dietary supplements comprising the improved beadlets. Preferred dietary supplements have been formulated as an aid to ocular 15 health. The present invention is also directed to methods of using the beadlets and dietary supplements for improving nutritional health. The methods of the present invention are particularly directed to the enhancement of ocular health and the prophylaxis of retinal disorders, including age-related macular degeneration.

One advantage of the beadlets of the present invention is that they provide one or 20 more xanthophylls and one or more carotenes in a single beadlet formulation. Because these molecules contain multiple, conjugated double bonds, they are highly susceptible to degradation. Consequently, antioxidants have been required in dietary supplements to prevent premature oxidation of xanthophylls and carotenes during processing, manufacture, and storage. By coupling these mutually vulnerable components and the necessary 25 antioxidants in one beadlet, the amount of stabilizing (antioxidant) component in the overall

dietary supplement can be reduced, since the stabilizing components are distributed more proximately to the xanthophylls and carotenes, thereby concurrently stabilizing both of these carotenoids. In addition, the carotenes and xanthophylls, together in a single beadlet, may serve to stabilize each other. Since the stabilizing antioxidant components are often in excess of the active xanthophyll and carotene component, the total amount of the stabilizing antioxidant and other excipients including osmolality modifiers and polymers can become important, especially in a dosage form in which the presence of excess excipient diminishes the amount of the nutritional components that can be contained in the dosage form. In other words, an excess of excipient may displace crucial amounts of other vitamins, minerals or other dietary substances in the dosage form.

Another advantage of the beadlets of the present invention is that the juxtaposition of the carotenes and xanthophylls in a single beadlet, with or without absorption enhancing excipients, may allow for absorption synergy and/or activity synergy, leading to enhanced nutritional efficacy of the dietary supplement. Such synergy may arise, for example, when their properties – physical, chemical or physiological – are sufficiently similar that the bioavailability or site-specific targeting of these active ingredients may be manipulated concurrently using the single beadlet technology.

A related advantage of the coupling of these and other nutritional components into one beadlet is the potential for manipulating and improving competitive absorption of these agents. For example, if the beadlets are also comprised of a timed-release polymer, the release of the nutritional components may be controlled and thus synchronized, e.g., delivering them to the upper intestine at the same time where solubilization by chylomicra forming bile salts can facilitate synchronous absorption.

Another advantage of the beadlets is that, as a practical matter of formulation, the amounts of xanthophyll and carotene can be manipulated better as a single beadlet entity, as

opposed to adjusting the individual xanthophyll and carotene components of the finished dietary supplement. In other words, the beadlet composition may be significantly altered while the dietary supplement preparation using the same size and number of beadlets (but now different beadlet composition) would be unaffected. For example, little or no change in
5 dietary supplement preparation would be expected for a change in formulations in which a 3% lutein/0% zeaxanthin/3% weight/weight ("w/w") Vitamin A containing beadlet was replaced by a 0% lutein/ 3% zeaxanthin/3% w/w Vitamin A containing beadlet. And in both cases the amount of both the complementary antioxidant and other supplementary constituents within the beadlet may remain invariant. This simplifies the reformulation
10 process of a complex dietary supplement (often containing 30 or more components) and would be useful in view of the need to respond to new scientific information directing modifications of nutritional components of dietary supplements. This advantage greatly improves the turn-around time and reduces the cost of reformulation of such dietary supplements.

15 Still another advantage of the beadlets of the present invention is that they allow better manipulation of the appearance of the dietary supplement. Because many carotenes and xanthophylls have multiple, conjugated double bonds, they are intensely colored (oranges to red) and hydrophobic. Thus, specialized techniques have been generally required to compress tablets containing such components so that the dietary supplement form does not
20 crumble and the components do not "bleed" within the supplement form, and to coat the beadlet-containing supplement form uniformly and consistently so that no unattractive discoloration or pitting occurs. Combining the carotenes and xanthophylls in a single beadlet lessens the problems of tabletting and tablet coating. Thus, once having developed a dietary supplement using a coating technology capable of screening and disguising imperfections
25 introduced by the beadlet onto the surface of the dosage form, minor reformulations of a

single complex beadlet, would obviate the requirement to redevelop the entire dietary supplement coating and tabletting technologies.

The application of the beadlet technology of the present invention to dietary supplements provides, and facilitates development of, enhanced nutritional supplementation.

5 Such technology may aid in increasing bioavailability of the dietary substances and also provide ease in modifying compositions containing xanthophylls/carotenes and complementary antioxidants within the supplement. Such improvements are believed to be particularly useful in the enhancement of ocular nutrition and improved ocular health.

10 **Detailed Description of the Invention**

The present invention is directed to improved beadlet formulations, improved dietary supplement formulations comprising the improved beadlets and methods of use. As used herein, "dietary supplement(s)" or the shortened form, "supplement(s)," refer to any finished, 15 dietary supplement dosage form containing dietary substances and suitable for ingestion by a host, e.g., human or other mammal.

The beadlets of the present invention comprise one or more xanthophylls; one or more carotenes or retinoids or combinations thereof; one or more antioxidants; and one or more solidifying agents.

20 As used herein, "xanthophylls" refer to hydroxy- and keto-oxidized carotenes and their derivatives; "carotenes" refer to any of the 40-carbon carotenes and their derivatives; "retinoids" refers to the 20-carbon Vitamin A (retinol) and its derivatives; and "carotenoids" refers to any of the xanthophylls, carotenes and retinoids or combinations thereof. Carotenoids may be synthetically derived or purified from natural sources. Synthetic 25 preparations may contain different isomers of carotenoids than those contained in the natural

preparations. Depending on intended use, natural, synthetic or mixtures of both types of carotenoids may be included in the beadlets of the present invention.

The xanthophyll component may be obtained from various sources such as vegetables and herbal components, such as corn, leafy green vegetables and marigolds; marine sources, 5 such as krill; or microorganic sources, such as algae and gene-engineered bacterial or yeast sources. Xanthophylls may also be synthesized by methods known in the art and are available from various manufacturers. Examples of xanthophylls include, but are not limited to, lutein, zeaxanthin, astaxanthin, canthaxanthin, cryptoxanthin and related oleoresins (e.g., fatty acid mono and di-esters of xanthophylls). The xanthophyll purity and concentration in 10 the various commercial sources will vary. For example, some sources may provide about a 1% weight/weight ("w/w") or less of xanthophyll in oil while other sources, e.g., Kemin Laboratories, Inc. (Des Moines, Iowa), may provide a source in excess of 20% w/w xanthophyll in oil. Xanthophyll sources may be preparations of individual xanthophylls or combinations thereof. For example, a xanthophyll preparation may comprise lutein as the 15 sole xanthophyll or a combination of lutein and zeaxanthin. The inclusion of a combination of xanthophylls in the beadlets, and in particular ratios, may be particularly important when it is the intention to deliver such combinations to the host in ratios similar to those found in the retina broadly, or in the macula or fovea of the eye, specifically, or in other ratios which, when ingested, support the ratios in the host tissues. Xanthophylls may also included in the 20 beadlets as conjugated derivatives, e.g., oleoresins of xanthophylls, as exemplified above.

The carotene, retinoid or combinations thereof component (hereinafter referred to as "carotene(s)/retinoid(s)") may be obtained from various sources such as vegetable and herbal sources, such as corn and leafy vegetables, and fermentation product sources available from the biotech industry. The carotenes/retinoids may also be synthesized by methods known in 25 the art. Examples of carotenes include, but are not limited to, alpha-, beta-, gamma-, delta-,

epsilon- and psi-carotene, isomers thereof. Examples or retinoids include, but are not limited to, Vitamin A and Vitamin A analogs (e.g., retinoic acid). The carotene/retinoid purity and concentration in the various commercial sources will vary. For example, some sources may provide about a 1% w/w or less of carotene/retinoid in oil, or as an oil suspension, or in a 5 protected dry form, e.g., a beadlet.

The concentrations of the xanthophylls and carotenes/retinoids in the beadlets will vary, but will be in amounts useful for inclusion of the beadlets in dietary supplements. In general, the combined concentration of xanthophylls and carotenes/retinoids in the beadlets will be in the range of about 0.1 to 10 % w/w. Preferred carotenoid concentrations, which are 10 generally dependent on the selection of particular carotenes/retinoids and xanthophylls and their relative ratios, will be about 0.5 to 7 % w/w. The individual concentrations of the xanthophylls and the carotenes/retinoids will not necessarily be the same. Preferred beadlets will have a concentration ratio from about 1:10 to about 10:1 of xanthophylls:carotenes/retinoids and the most preferred beadlets will have concentration 15 ratios from about 2:1 to about 1:2 of xanthophylls:carotenes/retinoids.

The most preferred beadlets of the present invention will comprise 0.5 to 7% w/w of lutein/zeaxanthin (xanthophylls) and 0.5 to 7% w/w of β -carotene (carotenes/retinoids).

As stated above, the beadlets will also contain one or more antioxidants. The 20 antioxidants can be hydrophobic or hydrophilic. The antioxidants serve to inhibit the oxidative, photochemical and/or thermal degradation of the carotenoid components. Since antioxidants are also thought to be useful in nutritional health, they may also provide some nutritional benefit to the host. In general, the antioxidants will be natural antioxidants or agents derived therefrom. Examples of natural antioxidants and related derivatives include, but are not limited to, vitamin E and related derivatives, such as tocotrienols, alpha-, beta-, 25 gamma-, delta- and epsilon-tocopherol, and their derivatives, such as the corresponding

acetates, succinates; Vitamin C and related derivatives, e.g., ascorbyl palmitate; and natural oils, such as oil of rosemary. Preferred beadlets will contain one or more hydrophobic antioxidants. The amount of antioxidant(s) contained in the beadlet will be an amount effective to inhibit or reduce the oxidative, photochemical and/or thermal degradation of the carotenoid components. Such an amount is referred herein as "an effective amount of one or more antioxidants." In general, such an amount will range from about 0.1 to 10 times the amount of the xanthophyll and carotene/retinoid components and any other chemically sensitive components present, e.g., bioflavonoids. Preferred beadlets, which will generally comprise about 0.5-7% w/w of carotenoids alone, or including bioflavonoids, will contain about 2 to 10% w/w of antioxidant. The most preferred beadlets will contain Vitamin E and, optionally, ascorbyl palmitate.

The beadlets will also comprise one or more solidifying, bulking and agglomerating agents (collectively referred to herein as "solidifying agent(s)"). The solidifying agent(s) aid in transforming the carotenoid and antioxidant components into a solid suitable for granulation, tableting or blending prior to encapsulation, of the beadlet in the dietary supplement. The solidifying agents are particularly useful when the carotenoid/antioxidant components are in oils or oil suspensions. Examples of solidifying agents useful in the preparation of the beadlets include, but are not limited to, sucrose, glucose, fructose, starches (e.g., corn starch), syrups (e.g., corn syrup), and ionic and nonionic polymers including, but not limited to, PEGs and other poly ether-like alkoxy cellulosics (HPMC), gellan, carrageenans, *Eucheuma gelatinae*, hyaluronates, chondroitin sulfate, pectins, and proteins, (e.g., collagen or their hydrolyzed products (e.g., gelatins or polypeptides)). Other solidifying agents known to those skilled in the art of beadlet and dietary supplement preparation may also be used in the preparation of the beadlets of the present invention. The

amount of solidifying agent(s) will vary, depending on the other components contained in the beadlet, but will generally comprise the majority weight and volume of the beadlet.

Optionally, the beadlets of the present invention may also contain one or more bioflavonoids and/or glycosidic bioflavonoids. Bioflavonoids, or "flavonoids," are flavone-
5 and isoflavone-like structures found primarily in fruits and vegetables. Bioflavonoids are commercially available or may be synthesized by methods known in the art. Examples of bioflavonoids include, but are not limited to, quercetin, acacetin, liquiritin, rutin, taxifolin, nobiletin, tangeretin, apigenin, chrysin and kaempferol, and their derivatives, such as the corresponding methoxy-substituted analogs. The bioflavonoids may be useful in nutritional
10 health as modulators of the rates of *in vivo* enzyme-mediated reactions. The bioflavonoids may also provide antioxidant activity and may be included in the beadlet for this purpose.

Other oils may be present in the beadlets of the present invention. The beadlets will typically comprise an amount of vegetable oils or oleoresins, since the separate carotene/retinoid and/or xanthophyll components to be added to the beadlets are generally
15 commercially available as a diluted vegetable oil or oil suspension, or as an oleoresin extract. Such an amount of oil/oleoresin typically ranges from about 1 to 100 times the xanthophyll or carotene content in the beadlet. For example, a xanthophyll extract to be included in a beadlet may contain 20% w/w lutein, 2% w/w zeaxanthin and 78% vegetable oil/oleoresin.
Other oils may also be included in the beadlets.

20 The beadlets of the present invention may also comprise additional excipients useful in preparing and finishing the beadlets. Such excipients may include timed-release polymer coating agents useful in prolonging dissolution of the beadlet in the digestive tract. Examples of such polymers include, but are not limited to ionic and nonionic polymers, such as PEGs and other poly ether-like alkoxy celluloses (HPMC), gellan, carrageenans, *Eucheuma gelatinae*, starch, hyaluronates, chondroitin sulfate, pectins, and proteins, e.g., collagen.
25

Since the xanthophyll/carotenes are highly pigmented, coating technology may be applied to the beadlet in order to provide a beadlet of uniform color. Examples of color coating agents may include, but are not limited to, polymers, colorants, sealants and surface active agents including, not limited to, fatty acids and esters, di- and triglycerides, phospholipids including 5 mono- and di-alkyl glyceryl phosphates, nonionic agents (sugars, polysaccharides, e.g., HPMC and polysorbate 80) and ionic agents.

The above-described ingredients contained in the beadlets may, in some cases, form microspheres within the beadlet. The beadlets may be of various size and shape. In general, however, the beadlets will be spheroid with an approximate diameter of about 0.2 microns to 10 800 microns.

The beadlets may be manufactured using a number of techniques known in the art. For example, the beadlets may be prepared by blending and granulation of the ingredients, followed by drying. The details of these processes may vary according to the sequence of addition, duration and conditions for granulation, and techniques employed for drying. 15 Preferred methods will include a low-temperature, low light-exposure drying step capable of maintaining stability of the beadlet. An inert, or reduced-oxygen, atmosphere may also be employed in the manufacture of the beadlets in order to further reduce degradation of sensitive components.

The following Examples 1-6 illustrate preferred beadlets of the present invention. 20 The amount of water present in the following beadlet examples may vary due to process and storage conditions but will generally range from about 1-10% w/w; as such, the other component percentage amounts may fluctuate slightly, but will be in the same relative proportion with respect to each other.

Example 1

Ingredient	Amount (% w/w)
Beta Carotene (natural)	3
Lutein/zeaxanthin (natural)	3
Hydrolyzed Gelatin	30
Vegetable Oil/Oleoresin	23
Sucrose	14.6
Food Grade Corn Starch	17
Ascorbyl Palmitate	2.7
Tocopherol(s)	1.7
Water	5

Example 2

Ingredient	Amount (% w/w)
Beta Carotene (natural)	3
Lutein	2.7
Zeaxanthin	0.3
Hydrolyzed Gelatin	30
Vegetable Oil/Oleoresin	23
Sucrose	14.6
Food Grade Corn Starch	17
Ascorbyl Palmitate	2.7
Tocopherol(s)	1.7
Water	5

Example 3

Ingredient	Amount (% w/w)
Beta Carotene (natural)	3
Lutein	1.5
Zeaxanthin	1.5
Hydrolyzed Gelatin	30
Vegetable Oil/Oleoresin	23
Sucrose	14.6
Food Grade Corn Starch	17
Ascorbyl Palmitate	2.7
Tocopherol(s)	1.7
Water	5

5

Example 4

Ingredient	Amount (% w/w)
Beta Carotene (natural)	3
Lutein	1.0
Zeaxanthin	1.0
Astaxanthin	1.0
Hydrolyzed Gelatin	30
Vegetable Oil/Oleoresin	23
Sucrose	14.6
Food Grade Corn Starch	17
Ascorbyl Palmitate	2.7
Tocopherol(s)	1.7
Water	5

Example 5

Ingredient	Amount (% w/w)
Beta Carotene (natural)	2
Lutein	1.0
Zeaxanthin	1.0
Astaxanthin	1.0
Quercetin	1.0
Hydrolyzed Gelatin	30
Vegetable Oil/Oleoresin	23
Sucrose	14.6
Food Grade Corn Starch	17
Ascorbyl Palmitate	2.7
Tocopherol(s)	1.7
Water	5

5

Example 6

Ingredient	Amount (% w/w)
Beta Carotene (natural)	1
Lutein/zeaxanthin	5
Hydrolyzed Gelatin	31.6
Vegetable Oil/Oleoresin	24
Sucrose	18
Food Grade Corn Starch	16
Ascorbyl Palmitate	2.7
Tocopherol(s)	1.7

As stated above, the beadlets of the present invention may be incorporated in various dietary supplements. The dietary supplements of the present invention may be formulated as powders, two-piece hard shell capsules, gel-caps, tablets, or any other solid or semi-solid form that can be taken orally. The dietary supplements will generally comprise other vitamins, minerals and excipients. The amount of beadlets incorporated in the dietary supplements will vary, depending on various factors, such as total weight or volume of the dietary supplement form, the specific nutritional health objective, the presence of other components in the supplement, and so on. In general, however, the beadlets will be incorporated in the dietary supplements in an amount of from about 1 to 50% w/w of dietary supplement. Preferred dietary supplements will comprise the present invention beadlets in an amount of from 2 to 15 % w/w of dietary supplement.

The types and amounts of the vitamins and minerals contained in the supplement, other than those contained in the beadlets, will depend on the type of supplement being prepared, i.e., the intended area of health to be treated/enhanced by the supplement and the dosing regimen.

The dietary supplements may also contain herbal or plant preparations or extracts. Examples of herbal or plant preparations or extracts useful in the dietary supplements include, but are not limited to, extracts from teas, fruits and vegetables (e.g., citrus fruits); dried, chopped or powdered leaves or films from vegetable products (e.g., berries, spinach, kale); extruded oils and oil soluble nutrients (e.g., grape seed extract); and hydrolyzed or natural protein, peptide and amino acid components.

Preferred dietary supplements comprising the beadlets of the present invention are intended to aid in ocular health. Various vitamins and minerals, in addition to the beadlets, may be added to such supplements, but in general, the supplements will contain Vitamin B-2 in an amount of about 0.5 to 40 milligrams ("mg")/tablet; Vitamin C in an amount of about

15 to 500 mg/tablet; Vitamin E in an amount of about 4 to 300 IU/tablet; copper in an amount of about 0.75 to 6 mg/tablet; manganese in an amount of about 0 to 10 mg/tablet; selenium in an amount of about 10 to 80 micrograms ("mcg")/tablet; and zinc (e.g., as zinc acetate) in an amount of about 7.5 to 80 mg/tablet. These quantities correspond to conventional tablets or 5 capsules ranging in weight from about 200 mg to 1.5 grams.

Excipients useful in the dietary supplements include viscosity agents, emulsifiers, binding agents, buffers, bulking agents, coloring agents and water soluble coatings. Such excipients are well known in the art for preparing dietary supplements. Preferred excipients for inclusion in ocular-type dietary supplements include salts and acids (e.g., dicalcium 10 phosphate, ascorbyl palmitate, calcium carbonate, calcium silicate, croscarmellose sodium, magnesium stearate, sodium ascorbate, sodium benzoate, sorbic acid), polymers and saccharides (e.g., HPMC, microcrystalline cellulose ("MCC")), gelatin, polyethylene glycol, starch, and sucrose), surface active agents and oils or waxes (e.g., magnesium stearate, lecithins, phospholipids, tocopherols, vegetable oils and oleoresin, carnauba wax), inert 15 solids and colorants (e.g., silicon dioxide, titanium dioxide), and coating materials (e.g., the Opadry[®] coating materials).

The following Examples 7-12 are examples of preferred dietary supplements. Although the nutritional components and amounts are listed separately, such components are often added to the dietary supplement preparation as mixtures of the component along with 20 ancillary excipients. For example, in Example 7, copper is actually added as 20 mg of a 10% w/w copper-amino acid chelate, yielding a final amount of 2.0 mg of copper. The chelate counter-ion is considered, for this accounting, an "ancillary excipient" as are other such unspecified inactive components/excipients. Specific, identifiable excipients added to the preparation, are listed separately.

Example 7

A preferred dietary supplement tablet of the present invention, incorporating the beadlets of

Example 1:

Ingredient	Amount
Beadlet of Example 1	83 mg
Other nutrients:	
Vitamin B-2	6.5 mg
Vitamin C	200 mg
Vitamin E	75 IU
Copper	2 mg
Manganese	5 mg
Selenium	20 mcg
Zinc (acetate)	30 mg
Excipients:	
Dicalcium phosphate	108 mg
HPMC (hydroxypropylmethylcellulose)	93 mg
MCC (microcrystalline cellulose)	46.5 mg
Magnesium stearate	31 mg
Silicon dioxide	34.5 mg
Sucrose	0.9 mg
Polyethylene glycol	2.7 mg
Gelatin	67.7 mg
Polysorbate 80	0.2 mg
Sodium benzoate	0.15 mg
Sorbic acid	0.3 mg
Titanium dioxide	7 mg
Carnauba wax	0.04 mg
Ancillary excipients	121 mg

Example 8

A preferred dietary supplement tablet of the present invention, incorporating any of the beadlets of Example 2-6, or combinations thereof:

Ingredient	Amount
Beadlets	83 mg
Other nutrients:	
Vitamin B-2	6.5 mg
Vitamin C	200 mg
Vitamin E	75 IU
Copper	2 mg
Manganese	5 mg
Selenium	20 µg
Zinc (acetate)	30 mg
Excipients:	
Dicalcium phosphate	108 mg
HPMC (hydroxypropylmethylcellulose)	93 mg
MCC (microcrystalline cellulose)	46.5 mg
Magnesium stearate	31 mg
Silicon dioxide	34.5 mg
Sucrose	0.9 mg
Polyethylene glycol	2.7 mg
Gellatin	67.7 mg
Polysorbate 80	0.2 mg
Sodium benzoate	0.15 mg
Sorbic acid	0.3 mg
Titanium dioxide	7 mg
Carnauba wax	0.04 mg
Ancillary excipients	121 mg

Example 9

A preferred dietary supplement tablet of the present invention incorporating any of the beadlets of Example 1-6, or mixtures thereof:

Ingredient	Amount
Beadlets	80-120 mg
Other nutrients:	
Vitamin B-2	2 mg
Vitamin C	65 mg
Vitamin E	15 IU
Copper	1 mg
Manganese	3.5 mg
L-Selenomethionine	50 µg
Zinc (acetate)	10 mg
Excipients:	
Calcium carbonate	106 mg
MCC (microcrystalline cellulose)	87 mg
Magnesium stearate	6 mg
Silicon dioxide	9 mg
HPMC	15.3 mg
Calcium silicate	1.4 mg
Starch	11.7 mg
Titanium dioxide	5 mg
Croscarmellose sodium	6 mg
Polysorbate 80	0.2 mg
Dicalcium phosphate	4 mg
Fish gelatin	3.7 mg
Polyethylene glycol	2.5 mg
Carnauba wax	0.018 mg
Ancillary excipients	47.3 mg

Example 10

A preferred dietary supplement gelatin capsule of the present invention incorporating any of the beadlets of Example 1-6, or mixtures thereof:

Ingredient	Amount
Beadlets	80-120 mg
Other nutrients:	
Thiamin (Vitamin B-1)	1.4 mg
Riboflavin (Vitamin B-2)	1.6 mg
Pyridoxine (Vitamin B-6)	2 mg
Cyanocobalamin	0.001 mg
Niacin	18 mg
Ascorbic Acid	60 mg
Vitamin E (d-alpha-tocopherol succinate)	9 IU
Copper (as copper gluconate)	0.5 mg
Zinc (as zinc acetate)	5 mg
Manganese (as citrate)	1 mg
Folate	0.2 mg
Biotin	0.15 mg
Pantothenic Acid	6 mg
Selenium	0.07 mg
Bilberry Herb Powder	40 mg
Citrus Bioflavonoid Complex Powder	250 mg
Grape Seed Extract with Leucoanthocyanins	10 mg
Taurine	50 mg
Polyphenol Catechins of Green Tea Extract	50 mg
Spinach Leaf Powder	50 mg
n-Acetyl L-Cysteine (Anhydrous)	50 mg
Excipients:	
Vegetable Derived Magnesium Stearate	13 mg
Fine Silica Powder	10 mg
Croscarmellose Sodium	20 mg
White Opaque Gelatin Capsule	115 mg
Ancillary Excipients	0-100 mg

Example 11

A preferred dietary supplement gelatin capsule of the present invention incorporating any of the beadlets of Example 1-6, or mixtures thereof:

Ingredient	Amount
Beadlets	80-120 mg
Other nutrients:	
Thiamin (Vitamin B-1)	0.8 mg
Riboflavin (Vitamin B-2)	1.1 mg
Pyridoxine (Vitamin B-6)	1.2 mg
Cyanocobalamin	0.001 mg
Niacin	16 mg
Ascorbic Acid	60 mg
Vitamin E (d-alpha-tocopherol succinate)	9 IU
Folate	0.025 mg
Biotin	0.3 mg
Pantothenic Acid	4 mg
Selenium	0.05 mg
Excipients:	
Vegetable Derived Magnesium Stearate	10 mg
Fine Silica Powder	8 mg
Croscarmellose Sodium	12 mg
White Opaque Gelatin Capsule	95 mg
Ancillary Excipients	0-100 mg

Example 12

A preferred dietary supplement gelatin capsule of the present invention, incorporating any of the beadlets of Example 1-6, or mixtures thereof:

Ingredient	Amount	Ingredient	Amount
Beadlets	25-100 mg	Magnesium	16.67 mg
Other nutrients:		Calcium	33.33 mg
Vitamin C	80 mg	Potassium	33 mg
Vitamin E	70 IU	Citrus Bioflavonoids	133.33 mg
Vitamin B-1	1 mg	Polyphenol Catechins	33.33 mg
Vitamin B-2	1.133 mg	Spinach Leaf Powder	16.67 mg
Niacin	13.33 mg	Bilberry Herb	20 mg
Vitamin B-6	2 mg	Blueberry Fruit Powder	10 mg
Folate	133.33 mcg	Leucoanthocyanins	3.33 mg
Vitamin B-12	10 mcg	n-acetyl l-cysteine	16.67 mg
Biotin	50 mcg	Glutathione	5 mg
Pantothenic Acid	6.67 mg	Alpha Lipoic Acid	3.33 mg
Vitamin D	26.67 mg	Excipients:	
Selenium	33.33 mcg	Vegetable Derived Magnesium Stearate	13 mg
Zinc	5 mg	Fine Silica Powder	10 mg
Copper	0.67 mg	Croscarmellose Sodium	20 mg
Manganese	0.67 mg	White Opaque Gelatin Capsule	115 mg
Chromium	33.33 mcg	Ancillary Excipients	0-100 mg

5 The dietary supplements of the present invention may be used to treat various disorders and to enhance the health of particular tissues and the overall health of the patient.

Preferably, the dietary supplements of the present invention will be used to treat ocular diseases and disorders and to improve the ocular health of the patient. The methods of

the present invention are particularly directed to the administration of the dietary supplements for improving the ocular health of patients under treatment for glaucoma, and other diseases and disorders of the retina and its support tissues, particularly age related macular degeneration, retinal ischemia, acute retinopathies associated with trauma, post-surgical complications, the damage associated with laser therapy including photodynamic therapy (PDT), and surgical light induced iatrogenic retinopathy. As used herein, "retina or optic nerve head neuropathy" refers to any of the foregoing diseases or other retinal or optic nerve head neurodegenerative diseases.

The use of the dietary supplements of the present invention to prevent, treat or ameliorate macular degeneration is a particularly preferred embodiment of the methods of the present invention. As stated in the Background of the Invention, there is some indication that certain xanthophylls, e.g., lutein and zeaxanthin, may be useful/necessary in the prevention/treatment/amelioration of macular degeneration. The present invention dietary supplements contain xanthophylls and carotenes and/or retinoids together in beadleted form such that such supplement compositions are believed to provide improved nutrition of the macula and, hence, improved methods of preventing, treating or ameliorating macular degeneration.

Dosing regimens will vary, depending on the particular dietary supplement components and amounts, and the age, weight, sex, diet and ancillary medication taken by the patient and severity of the condition to be treated (or prophylaxis to be obtained). Dosing regimens will also depend on the form of the dietary supplement and the potency of the dietary supplement to be taken. Such determinations may be assessed by clinicians skilled in the art but, in general, 1-4 dietary supplements will be taken per day.

I Claim:

1. A beadlet comprising one or more xanthophyll(s), one or more carotene(s)/retinoid(s), one or more antioxidant(s) and one or more solidifying agent(s).
- 5 2. A beadlet according to Claim 1, wherein the xanthophyll(s) is/are selected from the group consisting of lutein, zeaxanthin, astaxanthin, canthaxanthin and cryptoxanthin.
- 10 3. A beadlet according to Claim 1, wherein the carotene(s)/retinoid(s) is/are selected from the group consisting of alpha-, beta-, gamma-, delta-, epsilon- and psi-carotene, Vitamin A and Vitamin A analogs.
- 15 4. A beadlet according to Claim 1, wherein the antioxidant(s) is/are selected from the group consisting of: tocotrienols, alpha-, beta-, gamma-, delta- and epsilon-tocopherol, and their corresponding acetates and succinates; Vitamin C, ascorbyl palmitate and related derivatives; oil of rosemary and natural antioxidant oils.
- 20 5. A beadlet according to Claim 1, wherein the xanthophyll(s) are lutein and zeaxanthin and the carotene(s)/retinoid(s) is beta-carotene.
- 25 6. A beadlet according to Claim 5, comprising:
 - about 3% w/w beta carotene;
 - about 3% w/w lutein/zeaxanthin;
 - about 30% w/w hydrolyzed gelatin;
 - about 23% w/w vegetable Oil/Oleoresin;
 - about 15% w/w sucrose;
 - about 17% w/w food grade corn starch;

about 3% w/w ascorbyl palmitate;
about 2% w/w tocopherol (natural); and
water.

5 7. A beadlet according to Claim 5, wherein the ratio of lutein:zeaxanthin is in a range between 1:0.05 and 0.05:1.

10 8. A beadlet according to Claim 2, comprising:
about 3% w/w beta carotene;
about 1% w/w lutein;
about 1% w/w zeaxanthin;
about 1% w/w astaxanthin;
about 30% w/w hydrolyzed gelatin;
about 23% w/w vegetable Oil/Oleoresin;
about 15% w/w sucrose;
about 17% w/w food grade corn starch;
about 3% w/w ascorbyl palmitate;
about 2% w/w tocopherol (natural); and
water.

20 9. A beadlet according to Claim 1, further comprising one or more bioflavonoid(s).

10 10. A beadlet according to Claim 9, wherein the bioflavonoid(s) is/are selected
25 from the group consisting of: quercetin, acacetin, liquiritin, rutin, taxifulin, nobiletin,
tangeretin, apigenin, chrysins, kaempferol and derivatives thereof.

11. A beadlet according to Claim 10, comprising:

about 2% w/w beta carotene;

about 1% w/w lutein;
about 1% w/w zeaxanthin;
about 1% w/w astaxanthin;
about 1% w/w quercetin;
5 about 30% w/w hydrolyzed gelatin;
about 23% w/w vegetable Oil/Oleoresin;
about 15% w/w sucrose;
about 17% w/w food grade corn starch;
about 3% w/w ascorbyl palmitate;
10 about 2% w/w tocopherol (natural); and
water.

12. A dietary supplement comprising beadlets, vitamins and minerals, wherein the beadlets comprise one or more xanthophyll(s), one or more carotene(s)/retinoid(s), one or 15 more antioxidant(s) and one or more solidifying agent(s).

13. A dietary supplement according to Claim 12, wherein the xanthophyll(s) are selected from the group consisting of lutein, zeaxanthin, astaxanthin, canthaxanthin and cryptoxanthin.

20 14. A dietary supplement according to Claim 12, wherein the carotene(s)/retinoid(s) is/are selected from the group consisting of alpha-, beta-, gamma-, delta-, epsilon- and psi-carotene, Vitamin A and Vitamin A analogs.

25 15. A dietary supplement according to Claim 12, wherein the antioxidant(s) is/are selected from the group consisting of: tocotrienols, alpha-, beta-, gamma-, delta- and epsilon-tocopherol, and their corresponding acetates and succinates; Vitamin C, ascorbyl palimate and related derivatives; oil of rosemary and natural antioxidant oils.

16. A dietary supplement according to Claim 12, wherein the xanthophyll(s) are lutein and zeaxanthin and the carotene(s)/retinoid(s) is beta-carotene.

5 17. A dietary supplement according to Claim 16, wherein the beadlets comprise:
 about 3% w/w beta carotene;
 about 3% w/w lutein/zeaxanthin;
 about 30% w/w hydrolyzed gelatin;
 about 23% w/w vegetable Oil/Oleoresin;
 about 15% w/w sucrose;
 about 17% w/w food grade corn starch;
 about 3% w/w ascorbyl palmitate;
 about 2% w/w tocopherol (natural); and
 water.
10

15 18. A dietary supplement according to Claim 16, wherein the ratio of lutein:zeaxanthin is in a range between 1:0.05 and 0.05:1.

19. A dietary supplement according to Claim 13, wherein the beadlets comprise:
20 about 3% w/w beta carotene;
 about 1% w/w lutein;
 about 1% w/w zeaxanthin;
 about 1% w/w astaxanthin;
 about 30% w/w hydrolyzed gelatin;
 about 23% w/w vegetable Oil/Oleoresin;
 about 15% w/w sucrose;
 about 17% w/w food grade corn starch;
 about 3% w/w ascorbyl palmitate;
 about 2% w/w tocopherol (natural); and
 water.
25
30

20. A dietary supplement according to Claim 12, wherein the beadlets further comprise one or more bioflavonoid(s).

5 21. A dietary supplement according to Claim 20, wherein the bioflavonoid(s) is/are selected from the group consisting of: quercetin, acacetin, liquiritin, rutin, taxifulin, nobiletin, tangeretin, apigenin, chrysanthemum, kaempferol and derivatives thereof.

10 22. A dietary supplement according to Claim 21, wherein the beadlets comprise:
about 2% w/w beta carotene;
about 1% w/w lutein;
about 1% w/w zeaxanthin;
about 1% w/w astaxanthin;
about 1% w/w quercetin;
15 about 30% w/w hydrolyzed gelatin;
about 23% w/w vegetable Oil/Oleoresin;
about 15% w/w sucrose;
about 17% w/w food grade corn starch;
about 3% w/w ascorbyl palmitate;
20 about 2% w/w tocopherol (natural); and
water.

25 23. A dietary supplement according to Claim 12, comprising:
about 85 mg of the beadlets;
about 7 mg of Vitamin B-2;
about 200 mg of Vitamin C;
about 75 IU of Vitamin E;
about 2 mg of copper;
about 5 mg of manganese;
30 about 20 mcg of selenium; and

about 30 mg of zinc (acetate).

24. A dietary supplement according to Claim 17, comprising:

about 85 mg of the beadlets;
5 about 7 mg of Vitamin B-2;
about 200 mg of Vitamin C;
about 75 IU of Vitamin E;
about 2 mg of copper;
about 5 mg of manganese;
10 about 20 mcg of selenium; and
about 30 mg of zinc (acetate).

10

25. A method of supplementing the dietary health of a mammal or treating the mammal for diseases or disorders which comprises administering to the mammal a dietary supplement comprising beadlets, vitamins and minerals, wherein the beadlets comprise one or more xanthophyll(s), one or more carotene(s)/retinoid(s), one or more antioxidant(s) and 15 one or more solidifying agent(s).

15

26. A method according to Claim 25, wherein the supplement is administered to 20 the mammal to supplement the mammal's ocular health or to treat ocular diseases or disorders.

20

27. A method according to Claim 26, wherein the xanthophyll(s) are selected from the group consisting of lutein, zeaxanthin, astaxanthin, canthaxanthin and cryptoxanthin.

25

28. A method according to Claim 26, wherein the carotene(s)/retinoid(s) is/are selected from the group consisting of alpha-, beta-, gamma-, delta-, epsilon- and psi-carotene, Vitamin A and Vitamin A analogs.

29. A method according to Claim 26, wherein the antioxidant(s) is/are selected from the group consisting of: tocotrienols, alpha-, beta-, gamma-, delta- and epsilon-tocopherol, and their corresponding acetates and succinates; Vitamin C, ascorbyl palimate and related derivatives; oil of rosemary and natural antioxidant oils.
- 5
30. A method according to Claim 26, wherein the xanthophyll(s) are lutein and zeaxanthin and the carotene(s)/retinoid(s) is beta-carotene.
- 10
31. A method according to Claim 30, wherein the beadlets comprise:
- about 3% w/w beta carotene;
- about 3% w/w lutein/zeaxanthin;
- about 30% w/w hydrolyzed gelatin;
- about 23% w/w vegetable Oil/Oleoresin;
- about 15% w/w sucrose;
- about 17% w/w food grade corn starch;
- about 3% w/w ascorbyl palmitate;
- about 2% w/w tocopherol (natural); and
- water.
- 15
- 20
32. A method according to Claim 30, wherein the ratio of lutein:zeaxanthin is in a range between 1:0.05 and 0.05:1.

- 25
33. A method according to Claim 26, wherein the beadlet comprises:
- about 3% w/w beta carotene;
- about 1% w/w lutein;
- about 1% w/w zeaxanthin;
- about 1% w/w astaxanthin;
- about 30% w/w hydrolyzed gelatin;

about 23% w/w vegetable Oil/Oleoresin;
about 15% w/w sucrose;
about 17% w/w food grade corn starch;
about 3% w/w ascorbyl palmitate;
about 2% w/w tocopherol (natural); and
water.

5

34. A method according to Claim 26, wherein the beadlets further comprise one or more bioflavonoid(s).

10

35. A method according to Claim 34, wherein the bioflavonoid(s) is/are selected from the group consisting of: quercetin, acacetin, liquiritin, rutin, taxifulin, nobiletin, tangeretin, apigenin, chyrsin, kaempferol and derivatives thereof.

15

36. A method according to Claim 35, wherein the beadlets comprise:

20

about 2% w/w beta carotene;
about 1% w/w lutein;
about 1% w/w zeaxanthin;
about 1% w/w astaxanthin;
about 1% w/w quercetin;
about 30% w/w hydrolyzed gelatin;
about 23% w/w vegetable Oil/Oleoresin;
about 15% w/w sucrose;
about 17% w/w food grade corn starch;
about 3% w/w ascorbyl palmitate;
about 2% w/w tocopherol (natural); and
water.

25

37. A method according to Claim 26, wherein the dietary supplement comprises:

about 85 mg of the beadlets;
about 7 mg of Vitamin B-2;
about 200 mg of Vitamin C;
about 75 IU of Vitamin E;
5 about 2 mg of copper;
about 5 mg of manganese;
about 20 mcg of selenium; and
about 30 mg of zinc (acetate).

10 38. A method according to Claim 31, wherein the dietary supplement comprises:

about 85 mg of the beadlets;
about 7 mg of Vitamin B-2;
about 200 mg of Vitamin C;
about 75 IU of Vitamin E;
15 about 2 mg of copper;
about 5 mg of manganese;
about 20 mcg of selenium; and
about 30 mg of zinc (acetate).

20 39. A method according to Claim 26, wherein the ocular diseases or disorders are glaucoma, age related macular degeneration, retinal ischemia, acute retinopathies associated with trauma, ocular post-surgical complications, damage associated with laser therapy including photodynamic therapy (PDT), and surgical light induced iatrogenic retinopathy.

25 40. A method according to Claim 38, wherein the ocular diseases or disorders are glaucoma, age related macular degeneration, retinal ischemia, acute retinopathies associated with trauma, ocular post-surgical complications, damage associated with laser therapy including photodynamic therapy (PDT), and surgical light induced iatrogenic retinopathy.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/24439

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K35/78 A23L1/30 A23L1/303		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A23L		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, FSTA		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	US 5 955 102 A (IBRAHIM NAGUI ET AL) 21 September 1999 (1999-09-21) claims 1-16; examples	1-4, 9, 12-15, 20, 25-29, 34, 39, 40
X	WO 98 33494 A (KOSBAB JOHN V) 6 August 1998 (1998-08-06) page 47; claims 1,7; tables 3,4 page 20, line 9 - line 15 page 24, line 12 - line 30 page 39, line 29 - line 32	1-5, 7, 9, 12-16, 18, 20, 25-30, 32, 34, 39, 40
	-/-	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the International search report
30 November 2000		06.12.00
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax. (+31-70) 340-3016		Authorized officer Heezius, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/24439

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 11789 A (HOWARD FOUNDATION ;RAJPUT WILLIAMS JAYSHRI (GB); HOWARD ALAN NORMA) 26 March 1998 (1998-03-26)</p> <p>page 2, paragraph 3 page 9, paragraph 2 page 11, paragraph 3 page 13, paragraph 1 <u>claims 1,2,11,12,14,17</u></p>	1-4,9, 10, 12-15, 20,21, 25-29, 34,35, 39,40
X	<p>US 5 895 652 A (GIAMPAPA VINCENT C) 20 April 1999 (1999-04-20)</p> <p><u>claim 1</u></p>	1-4,9, 12-15, 20, 25-29, 34,39,40

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US 00/24439**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claims 25-40 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 00/24439

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5955102	A	21-09-1999	NONE		
WO 9833494	A	06-08-1998	AU 6141498 A	25-08-1998	
			EP 1021177 A	26-07-2000	
WO 9811789	A	26-03-1998	AU 4310597 A	14-04-1998	
			AU 4310697 A	14-04-1998	
			BR 9713212 A	04-04-2000	
			BR 9714341 A	11-04-2000	
			CN 1230956 A	06-10-1999	
			CN 1230875 A	06-10-1999	
			CZ 9900973 A	11-08-1999	
			EP 0930831 A	28-07-1999	
			GB 2349087 A,B	25-10-2000	
			WO 9812189 A	26-03-1998	
			GB 2317889 A	08-04-1998	
			GB 2317561 A,B	01-04-1998	
			NO 991351 A	19-05-1999	
			PL 332306 A	30-08-1999	
			PL 332312 A	30-08-1999	
			SK 35599 A	06-08-1999	
			US 6099854 A	08-08-2000	
US 5895652	A	20-04-1999	NONE		